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Background and Aims: The recurrent and chronic P. aeruginosa, biofilm colonization on the 
respiratory tract is the most prevalent cause of morbidity and mortality in patients with 
ventilator-associated pneumonia, cystic fibrosis (CF), chronic asthma and lung cancer. This 
situation has generated an urgent need for development of innovative, efficient and targeted 
treatments. Interest in host defence peptides (HDPs) has grown due to their potential 
therapeutic applications and their possible use against biofilm. This study, short, synthetic 
cationic peptides were tested for their anti-biofilm effectiveness as well as their ability to 
inhibit and disperse the ability of P. aeruginosa biofilms. 
 
Methods: The clinical isolates of P. aeruginosa from patients with chronic lung infections were 
used as a model to investigate inhibit and disperse of bacterial biofilms by synthetic short 
sequence defence peptides (HDPs). 
 
Results: The number of different novel anti-biofilm peptide candidates was tested against P. 
aeruginosa, and was found to exhibit an anti-microbial, anti-attachment as well as anti-
biofilm activity at concentrations in the low μg/ml range compare with current conventional 
antibiotics. Confocal laser scanning microscopy and CFU count revealed that peptide 
treatment inhibited biofilm formation resulting in bio-volume reduction followed by induced 
disruption of mature biofilms and other chronic virulent factors. Further, peptides 
significantly reduce the extracellular matrix substance of mature biofilms. 
 
Conclusion: These findings highlight the potential of novel peptides as a new group of 
antimicrobial weapons for disrupt biofilms and suggesting its potential use as a model for 
designing new treatment for chronic lung infections. 
 
 
